Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02461186
Other study ID # BAKMAL1501
Secondary ID
Status Withdrawn
Phase Phase 2/Phase 3
First received May 26, 2015
Last updated November 2, 2015
Start date June 2015
Est. completion date June 2017

Study information

Verified date November 2015
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority Myanmar: Ethical Review Committee
Study type Interventional

Clinical Trial Summary

Emerging resistance to artemisinins and their partner drugs severely threatens the treatment of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug policy, it is crucial to evaluate alternative antimalarial treatments.

The investigators here propose a randomized clinical trial comparing parasite clearance parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria in Myanmar stratified for the presence of "K13" mutation in the infecting parasite strains.


Description:

Primary Objective:

- To assess the parasite clearance half-life of arterolane-piperaquine compared to DHA-piperaquine in patients with artemisinin resistant uncomplicated falciparum malaria, defined by presence of the "K13" mutations in the infecting parasite strain.

Secondary Objectives :

- To assess the therapeutic efficacy of arterolane-piperaquine and DHA-piperaquine for the treatment of uncomplicated falciparum malaria or mixed infection (P.falciparum (PF) + a non-falciparum species) at Day 42, stratified by presence of artemisinin resistance in the infecting parasite strain.

- To assess the frequency of adverse events and serious adverse events of arterolane-piperaquine compared to DHA-piperaquine.

- To assess other efficacy parameters related to parasite clearance and parasite cure rate as well as the gametocyte carriage.

- To obtain pharmacokinetic (PK) and pharmacokinetic/pharmacodynamics (PK/PD) data on arterolane-piperaquine and DHA-piperaquine.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female aged = 18 year old

- Symptomatic malaria infection, i.e. history of fever or presence of fever >37.5°c (tympanic) within the last 24 hours.

- Microscopic confirmation of asexual stages of P.falciparum (may be mixed with non-falciparum species) with a parasitaemia >10,000 parasites/µL

- Able to take oral medication

- Willingness and ability of patients to comply with the study protocol for the duration of the study

- Written informed consent given to participate in the trial

Exclusion Criteria:

- Pregnancy or lactation (urine test for ß HCG to be performed on any woman of child bearing age 18 to 45 year old)

- P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL).

- Signs or symptoms indicative of severe malaria:

- Impaired consciousness

- Severe anaemia (Hct<15%)

- Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venipuncture sites

- Respiratory distress

- Severe jaundice

- Have taken a full course DHA-piperaquine, artemether-lumefantrin or other antimalarial treatment in the previous 42 days

- Known hypersensitivity to artemisinins or to piperaquine - defined as history of erythroderma/other severe cutaneous reaction or angioedema

- History of splenectomy

- History of taking medicinal products that are known to prolong the QTc interval, including:

- Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).

- Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.

- Certain antimicrobial agents, including agents of the following classes:

- macrolides (e.g. erythromycin, clarithromycin),

- fluoroquinolones (e.g. moxifloxacin, sparfloxacin),

- imidazole and triazole antifungal agent,

- pentamidine and saquinavir.

- The non-sedating antihistamines terfenadine, astemizole, mizolastine.

- Other drugs: cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.

- History of taking any drug which is known to be metabolised by the cytochrome enzyme CYP2D6 including flecainide, metoprol, imipramine, amitriptyline, clomipramine.

- Family history of sudden unexplained death, or personal or family history of predisposing cardiac conditions for arrhythmia/QT prolongation (including congenital long QT syndrome, arrhythmia, QTc interval greater than 450 milliseconds with either Bazett or Fridericia correction).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Arterolane maleate-piperaquine phosphate (Synriam)

Dihydroartemisinin-piperaquine phosphate (Duocotexin)


Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford Department of Medical Research, Lower Myanmar, Mahidol Oxford Tropical Medicine Research Unit

Outcome

Type Measure Description Time frame Safety issue
Primary Peripheral blood parasite half-life Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion >10,000 parasites/µL 2 years Yes
Secondary 42 day PCR corrected adequate clinical and parasitological response (ACPR) 42 days Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT00936767 - Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia Phase 2/Phase 3
Active, not recruiting NCT04009343 - Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials Phase 2/Phase 3
Completed NCT00682578 - A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan Phase 3
Completed NCT00959517 - Trial of Artesunate Combination Therapy in Pakistan Phase 2
Completed NCT03431714 - Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Phase 4
Recruiting NCT00902811 - Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Phase 4
Completed NCT01407887 - Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children Phase 2
Completed NCT00356005 - Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh Phase 2